Jupiter Neurosciences entered a licensing deal for PharmAla Biotech’s non-racemic MDMA asset ALA-002, granting Jupiter exclusive rights to develop the compound in the U.S. for neuropsychiatric disorders including PTSD and anxiety. Under the agreement, PharmAla receives $3.3 million upfront split between cash and Jupiter common stock, plus additional payments tied to dosing the first patient in a Phase 3 trial and to regulatory milestones. The parties also tied the transaction to a changing U.S. regulatory posture toward investigational psychedelic therapies. The deal also references existing government-sponsored clinical work using PharmAla’s MDMA supply through the Veterans Affairs Administration and the Defense Health Agency. For the sector, the Jupiter-PharmAla transaction adds another institutionalized pathway for MDMA programs in the U.S., in parallel with ongoing psychedelic development and heightened interest in PTSD and broader anxiety populations.